SDP-4 / SilkTech - LARVOL DELTA

Corrigendum to Silk-Derived Protein-4 Versus Vehicle Control in Treating Patients With Moderate to Severe Dry Eye Disease: A Randomized Clinical Trial. Am J Ophthalmol. 2025;269:315-326. (PubMed, Am J Ophthalmol) - No abstract available

Clinical • Dry Eye Disease • Ophthalmology

Therapeutic Effects of Topical Silk-Derived Protein 4 Formulation on Chloropicrin-Injured Mouse Cornea and Ex-vivo Rabbit Cornea (ARVO 2025) - "We found that 3 % SDP-4 treatment reversed CP induced corneal injury. Although, more studies are needed, this study provides a potential treatment for CP induced corneal injury."

Preclinical • Corneal Abrasion • Dry Eye Disease • Keratitis • Ocular Inflammation • Ophthalmology

Comprehensive Physicochemical Characterization and in Vitro Human Cell Culture Studies of an Innovative Biocompatible and Biodegradable Silk-Derived Protein Hydrolysate, SDP-4. (PubMed, ACS Omega) - "These findings demonstrate that SDP-4 is biocompatible with different types of human cells and safe at all of the doses studied. The unique physicochemical properties of SDP-4 revealed in this study demonstrate its favorable formulating ability for a variety of potential therapeutic applications."

Journal • Preclinical

Silk-Derived Protein-4 versus vehicle control in treating patients with moderate to severe dry eye disease: a randomized clinical trial. (PubMed, Am J Ophthalmol) - "To the best of our knowledge, this was the first-in-human use of SDP-4 in a clinical trial. SDP-4 is a first-in-class protein ingredient that offers a safe and multi-modal treatment approach for alleviating severe DED symptoms within a novel formulation."

Clinical • Journal • Dry Eye Disease • Ocular Inflammation • Ophthalmology

Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202) (clinicaltrials.gov) - P2; N=153; Completed; Sponsor: Silk Technologies, Ltd.; Recruiting ➔ Completed

Clinical • Trial completion • Dry Eye Disease • Ophthalmology

SilkTech Biopharmaceuticals completes enrollment of phase 2B clinical trial of SDP-4 for the treatment of the signs and symptoms of dry eye disease (Medical Alley Association) - "'The SDP-4 ophthalmic formulation provides an innovative protein-based approach to addressing the signs and symptoms of Dry Eye,' said Eric Donnenfeld, M.D...'The proposed use of the SDP-4 protein to provide a dual mechanism of action that both enhances wetting and spreading on the eye to stabilize the tear film, while also reducing inflammation offers a highly novel approach unlike other technologies either on the market or in development today.'"

Enrollment status • Media quote